New hope for advanced cancers: experimental drug KQB168 enters human testing
NCT ID NCT06994806
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new oral drug, KQB168, alone or with pembrolizumab, in adults with advanced solid tumors that have stopped responding to immunotherapy. The main goals are to find safe doses and see if the drug can shrink tumors. About 84 participants will take the drug daily and have frequent clinic visits for monitoring.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cleveland Clinic
RECRUITINGCleveland, Ohio, 44195, United States
-
Florida Cancer Specialists - Sarasota
RECRUITINGSarasota, Florida, 34232, United States
-
Mary Crowley Cancer Research Centers
RECRUITINGDallas, Texas, 75230, United States
-
Mayo Clinic - Jacksonville
RECRUITINGJacksonville, Florida, 32224, United States
-
Mayo Clinic - Phoenix
RECRUITINGPhoenix, Arizona, 85054, United States
-
Mayo Clinic - Rochester
RECRUITINGRochester, Minnesota, 55905, United States
-
NEXT Austin
RECRUITINGAustin, Texas, 78758, United States
-
NEXT Huston
RECRUITINGHouston, Texas, 77054, United States
-
NEXT Oncology
RECRUITINGSan Antonio, Texas, 78229, United States
-
NEXT Virginia
RECRUITINGFairfax, Virginia, 22031, United States
-
Sarah Cannon Cancer Institute at HealthONE
RECRUITINGDenver, Colorado, 80218, United States
-
USC Norris Comprehensive Cancer Center
RECRUITINGLos Angeles, California, 90033, United States
-
UT MD Anderson Cancer Center - Houston
RECRUITINGHouston, Texas, 77030, United States
-
University of Iowa
RECRUITINGIowa City, Iowa, 52242, United States
-
Yale Cancer Center- New Haven
RECRUITINGNew Haven, Connecticut, 06520, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a 'Universal' cancer target outsmart resistant blood cancers?
- Can a Cancer-Fighting virus shrink resistant tumors?
- ECMO in kids with cancer: a closer look at survival and risks
- New PET tracer could sharpen cancer detection
- Double-Drug attack on Hard-to-Treat cancers
- Engineered immune cells take on Hard-to-Treat cancers